HMGB1 Levels at Fetal Growth Restriction

NCT07857525 | Completed

• 1 other identifier: 2025-224
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The primary aim of this study is to evaluate HMGB1 levels in cases of intrauterine growth restriction (IUGR). The secondary aim is to determine whether the cerebroplacental ratio interacts with these levels. IUGR occurs when the fetus fails to reach its expected uterine growth potential due to fetal, maternal, and/or placental factors. IUGR occurs in approximately 10% of pregnancies worldwide. IUGR is associated with high perinatal morbidity and mortality rates. High motility group box 1 (HMGB1) is the most abundant member of the high motility group (HMG) protein family and is expressed in almost all human cells. HMGB1 is predominantly found in the nucleus and can also shuttle actively and passively between the nucleus and cytoplasm. During cell apoptosis and necrosis, HMGB1 is released from dying cells into the extracellular space. In high-risk pregnancies, particularly preeclampsia, HMGB1 levels are known to be elevated in the maternal circulation. A study investigating the possible link between sterile inflammation mediated by HMGB1 and the angiogenic imbalance observed in preeclampsia showed that high HMGB1 expression and its release from hypoxic trophoblasts play a critical role and contribute to angiogenic imbalance in preeclampsia.

Conditions

IUGR

Outcome Measures

Primary Outcomes (1)

• Serum HMGB1 Level

  Comparison of serum HMGB1 levels between pregnant women with intrauterine growth restriction (IUGR) and those without IUGR. Serum HMGB1 levels will be measured in venous blood samples using the ELISA method and compared between the two groups.

  From enrollment (20-41 weeks of gestation) until the collection and measurement of the serum HMGB1 sample.

Interventions

hmgb1 OTHER

hmgb1 levels

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

all patients with ıugr pregnancy are study group. The other control group is normal pregnancies.

You may qualify if:

• Pregnant women aged 18-45 years. Gestational age between 20 and 41 weeks. Pregnant women with IUGR or without IUGR. Willingness to participate in the study and provide written informed consent.

You may not qualify if:

• Small-for-gestational-age (SGA) pregnancy. Multiple pregnancy. History of inflammatory, autoimmune, or rheumatic disease. Inability to provide adequate study data or refusal to provide a blood sample.

Sponsors & Collaborators

• Karadeniz Technical University: lead

Study Sites (1)

Karadeniz technical university, school of medicine

Trabzon, Ortahisar, 61080, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITH DNA

plasma

MeSH Terms

Interventions

HMGB1 Protein

Intervention Hierarchy (Ancestors)

HMGB Proteins; DNA-Binding Proteins; Proteins; Amino Acids, Peptides, and Proteins; High Mobility Group Proteins; Chromosomal Proteins, Non-Histone; Nuclear Proteins; Nucleoproteins

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 30 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: assistant professor

Study Record Dates

• First Submitted: March 26, 2026
• First Posted: October 5, 2026
• Study Start: July 30, 2025
• Primary Completion: June 30, 2026
• Study Completion: September 30, 2026
• Last Updated: October 5, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)